Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis
NCT05739435Phase 2Active, not recruiting
- Sponsor
- Alumis Inc.
- Start
- Jan 2023
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of envudeucitinib in plaque psoriasis, sponsored by Alumis Inc.. Started Jan 2023; status: active, not recruiting.
02
Drugs
envudeucitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT05739435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05739435.